Clinical Trial: A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06393673) titled 'A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women' on April 27.

Brief Summary: A randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HS-10384 in postmenopausal women suffering from vasomotor symptoms.

Study Type: Interventional

Condition: Vasomotor Symptoms

Intervention: * Drug: HS-10384 tablet Dose 1

Administered orally QD

* Drug: HS-10384 tablet Dose 2

Administered orally QD

* Drug: HS-10384-matched placebo tablets

Administered orally QD

Recruitment Status: Not Yet Recruiting

Published by HT Digital Content Services with perm...